# Crucell Holland BV clinical trials: 37 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 37 trials with Crucell Holland BV as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Crucell Holland BV: 37 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/crucell-holland-bv

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 28, 2015 | NCT02561871 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers | Crucell Holland BV | Phase 1 | Completed | Respiratory Syncytial Viruses, Respiratory Tract Infections | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02561871) |
| September 7, 2015 | NCT02543268 | A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants | Crucell Holland BV | Phase 3 | Completed | Healthy | 329 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02543268) |
| May 12, 2015 | NCT02440035 | A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult... | Crucell Holland BV | Phase 1 | Completed | Healthy Participants | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02440035) |
| March 3, 2015 | NCT02376426 | A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants | Crucell Holland BV | Phase 1 | Completed | Healthy | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02376426) |
| March 3, 2015 | NCT02376400 | A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants | Crucell Holland BV | Phase 1 | Completed | Healthy | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02376400) |
| December 9, 2014 | NCT02313077 | A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants | Crucell Holland BV | Phase 1 | Completed | Healthy | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02313077) |
| December 1, 2014 | NCT02304185 | Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers | Crucell Holland BV | Phase 1 | Completed | Healthy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02304185) |
| August 15, 2014 | NCT02218125 | A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults | Crucell Holland BV | Phase 1 | Completed | Healthy | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02218125) |
| May 28, 2014 | NCT02148328 | Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults | Crucell Holland BV | Phase 1 | Completed | Influenza | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02148328) |
| November 25, 2013 | NCT01992276 | Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection | Crucell Holland BV | Phase 2 | Withdrawn | Influenza | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01992276) |
| September 10, 2013 | NCT01938352 | Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge | Crucell Holland BV | Phase 2 | Completed | Influenza | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01938352) |
| August 6, 2013 | NCT01917357 | A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject | Crucell Holland BV | Phase 3 | Completed | Diphtheria, Pertussis, Tetanus, Hepatitis B, Haemophilus Infections | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01917357) |
| July 8, 2013 | NCT01893177 | Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14) | Crucell Holland BV | Phase 3 | Completed | Influenza | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01893177) |
| April 25, 2013 | NCT01839760 | Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients | Crucell Holland BV | Observational | Completed | Influenza | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01839760) |
| December 28, 2012 | NCT01756950 | Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses | Crucell Holland BV | Phase 1 | Completed | Influenza | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01756950) |
| June 28, 2012 | NCT01631110 | Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains | Crucell Holland BV | Phase 3 | Completed | Influenza | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01631110) |
| June 28, 2012 | NCT01631071 | Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains | Crucell Holland BV | Not applicable | Completed | Influenza | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01631071) |
| June 12, 2012 | NCT01617239 | Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine | Crucell Holland BV | Phase 1 | Completed | Influenza | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01617239) |
| October 21, 2011 | NCT01457027 | A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the... | Crucell Holland BV | Phase 4 | Completed | Influenza | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01457027) |
| August 9, 2011 | NCT01412281 | Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers | Crucell Holland BV | Phase 3 | Completed | Influenza | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01412281) |
| August 1, 2011 | NCT01406418 | Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus | Crucell Holland BV | Phase 1 | Completed | Influenza | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01406418) |
| July 29, 2011 | NCT01405677 | Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine | Crucell Holland BV | Phase 2 | Completed | Hepatitis A | 308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01405677) |
| July 19, 2011 | NCT01397227 | A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge... | Crucell Holland BV | Phase 1/2 | Completed | Malaria | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01397227) |
| May 30, 2011 | NCT01362517 | Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B | Crucell Holland BV | Phase 3 | Completed | Diphtheria, Pertussis, Tetanus, Hepatitis B, Haemophilus Influenzae Infections | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01362517) |
| May 23, 2011 | NCT01357720 | Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination | Crucell Holland BV | Phase 4 | Completed | Diphtheria, Pertussis, Tetanus, Hepatitis B, Haemophilus Infections | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01357720) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 3 | 11 |
| Phase 4 | 6 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 36 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Virus Diseases | 19 |
| Influenza, Human | 18 |
| Hepatitis B | 4 |
| Rabies | 3 |
| Hepatitis A | 3 |
| Diphtheria | 3 |
| Whooping Cough | 3 |
| Tetanus | 3 |
| Haemophilus Infections | 3 |
| Acquired Immunodeficiency Syndrome | 2 |
| Respiratory Tract Infections | 1 |
| Malaria | 1 |
| Malaria, Falciparum | 1 |
| Adenoviridae Infections | 1 |
| Infections | 1 |
| Dyschromatosis symmetrica hereditaria 1 | 1 |
| Hemorrhagic Fever, Ebola | 1 |
| Hepatitis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Home automation companies in the United States](https://specstream.ai/data/businesses/home-automation-companies/united-states)
- [Chicken wings restaurants in the United States](https://specstream.ai/data/businesses/chicken-wings-restaurants/united-states)
- [Vegan restaurants in the United States](https://specstream.ai/data/businesses/vegan-restaurants/united-states)
- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
- [Guest houses in the United States](https://specstream.ai/data/businesses/guest-houses/united-states)
